Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | MAOB | P27338 | 4/20 | 0.62 |
| ▸ | PARP1 | P09874 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079080 | 0.81 | MAOA (0.46) | MAOAMAOBPARP1DRD2CHRM3 | |
| SCHEMBL19122972 | 0.78 | PARP1 (0.56) | MAOAMAOBPARP1HTR1A | |
| SCHEMBL28504031 | 0.78 | DRD2 (0.45) | MAOAMAOBPARP1DRD2OPRD1 | |
| SCHEMBL13074639 | 0.78 | PARP1 (0.56) | MAOAMAOBPARP1HTR1A | |
| SCHEMBL2249971 | 0.77 | PARP1 (0.58) | MAOAMAOBPARP1HTR1A | |
| SCHEMBL5544990 | 0.77 | PARP1 (0.58) | MAOAMAOBPARP1HTR1A | |
| SCHEMBL18181803 | 0.77 | PARP1 (0.58) | MAOAMAOBPARP1HTR1A | |
| SCHEMBL4596031 | 0.77 | PARP1 (0.54) | MAOAMAOBPARP1HTR1A | |
| SCHEMBL18474153 | 0.77 | PARP1 (0.54) | MAOAMAOBPARP1DRD2HTR1A | |
| Mellein SCHEMBL13925627 | 0.77 | MAOA (1.00) | MAOAMAOBPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021038241-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2021-03-04 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2003099757-A1 | STABILISATION OF ETHYLENICALLY UNSATURATED COMPOUNDS COMPRISING HYDROXYLAMINE DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2003-12-04 | — | — | WO | disclosed |
| EP-0230475-B1 | NOVEL UREA DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF AND HERBICIDE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4838924-A | NONPHYTOTOXIC | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
| US-4321204-A | Preparation of certain 2-methyl-2,3-dihydro-benzofuran-7-ols | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAOA 2885/4885MAOB 2140/4885PARP1 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.